abstract |
Described herein are hybrid antibodies targeted for use in the treatment of cancer. The antibodies have binding capabilities for Fcε receptors and Fcγ receptors, which may be achieved e.g. by grafting heavy chain constant domain sequences (e.g. CH2 and CH3 domains) derived from IgG to IgE. |